Skip to main content
Team Jack Foundation - Funding Research for Pediatric Brain Cancer

Follow on    Like on    SHOP   DONATE  

 
 
 

Funding Research for Pediatric Brain Cancer

  • Home
  • About
  • Research
  • Get Involved
    • Fundraise
    • Give
    • Events
    • Become a Sponsor
    • Volunteer
  • Families
 
 

Clinical Trial Finder

Filters

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

You can narrow your results further by searching each trial’s description for a specific word. Keep in mind that this will search the full description. We recommend carefully reviewing each trial information to ensure that it is an appropriate fit for you.

1 - 10 of 2019 Trials
  • [11C]Acetate PET in Patients With Glioma

    At each point that the patient will have [11C]-Acetate PET study, this will be compared with standard clinical MR imaging. Abbreviations: XRT - radiation therapy; TMZ - temozolomide (chemotherapy) Quantitative Image Data Analysis: The [11C]-Acetate uptake in tumor sites from images will be analyzed qualitatively by visual assessment, quantitatively using a standard uptake value (SUV) in the tumor relative to the contralateral normal brain, and the parameters obtained by compartmental modeling of dynamic data.

    18 Years and Over
    Learn More
  • 131I-IPA and Concurrent XRT in Recurrent GBM

    A multi-centre, open-label, single-arm, dose-finding phase I/II study to evaluate safety, tolerability, dosing schedule, and preliminary efficacy of carrier-added 4-L-[131I]iodo-phenylalanine (131I-IPA), administered as single or repetitive injections in patients with recurrent glioblastoma multiforme (GBM), concomitantly to 2nd line external radiation therapy (XRT) - IPAX-1

    18 Years and Over
    Learn More
  • 131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol

    This is a compassionate use protocol to allow patients with advanced neuroblastoma palliative access to 131I-metaiodobenzylguanidine (131I-MIBG).

    1 Year and Over
    Learn More
  • 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma

    This expanded access is the best available therapy/compassionate use designed to determine the palliative benefit and toxicity of 131I-MIBG in patients with relapsed/refractory neuroblastoma or metastatic pheochromocytoma who are not eligible for therapies of higher priority. Patients may receive a range of doses depending on stem cell availability and tumor involvement of bone marrow. Response rate, toxicity, and time to progression and death will be evaluated.

    N/A and Over
    Learn More
  • 131-I-MIBG Therapy for Refractory Neuroblastoma and Metastatic Paraganglioma/Pheochromocytoma

    Metaiodobenzylguanidine (MIBG) is a substance that is taken up by neuroblastoma or pheochromocytoma/paraganglioma tumor cells. MIBG is combined with radioactive iodine (131 I) in the laboratory to form a radioactive compound 131 I-MIBG. This radioactive compound delivers radiation specifically to the cancer cells and causes them to die. The purpose of this research protocol is to provides a mechanism to deliver MIBG therapy when clinically indicated, but also to provide a mechanism to continue to collect efficacy and toxicity data that will be provided.

    1 Year and Over
    Learn More
  • 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases

    Children with a neuroblastoma diagnose and central nervous system (CNS)/leptomeningeal metastases will be given up to 2 rounds of intracerebroventricular treatment with a radiolabelled monoclonal antibody, 131I-omburtamab to evaluate efficacy and safety

    N/A - 18 Years
    Learn More
  • 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours

    This is a phase I study of 177Lu-DOTA-TATE in combination with the PARP-inhibitor olaparib for treatment of patients with somatostatin receptor positive tumours detected by 68Ga-DOTA-TATE/TOC PET. The combination of a PARP inhibitor that will specifically target the repair mechanism, with ionising radiation causing SSB's might overcome the repair dependent survival of the tumour cells, making them more sensitive to β-emission and increase the probability of tumour cell death.

    18 Years and Over
    Learn More
  • 177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors

    Adults with leptomeningeal metastasis from solid tumors will be treated with 177Lu-DTPA-omburtamab, which is a radioactive labelling of a murine monoclonal antibody targeting B7-H3.

    18 Years and Over
    Learn More
  • 177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma

    Children and adolescents diagnosed with medullablastoma and with recurrent or refractory to frontline therapy will be treated with 177Lu-DTPA-omburtamab, which is a radioactive labelling of a murine monoclonal antibody targeting B7-H3.

    3 Years - 19 Years
    Learn More
  • 177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer.

    The purpose of this study is to determine the use of 177Lu-PP-F11N for imaging and therapy of patients with advanced medullary thyroid carcinoma (MTC). 177Lu-PP-F11N is a gastrin analogon, binding to cholecystokinin-2 receptors. This receptors show an overexpression on more than 90 % of medullary thyroid carcinomas. In the pilot (phase 0) study investigators will correlate the tumour detection rate with the surgery and histology (proof of concept study). Furthermore, kidney protection and dosimetry studies will be performed in order to determine the kidney protection protocol and starting activity for the dose escalation study in...

    18 Years and Over
    Learn More
← Previous 1 2 3 4 5 6 7 … 202 Next →
Powered By

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.

Team Jack Foundation

PO Box 607, Atkinson, NE 68713

For general information

Info@TeamJackFoundation.org

fundraiser information

Kylie@TeamJackFoundation.Org

media inquiries

Info@TeamJackFoundation.Org

other questions call

855-RUN-JACK

      

About

  • About Us
  • Our Focus
  • Team Jack All Stars
  • Jack Hoffman
  • Team Jack News
  • Team Jack Blog
  • Video Gallery
  • Husker Alumni Chapter

Get Involved

  • Fundraise
  • Give
  • Events
  • Become a Sponsor
  • Volunteer

Shop

  • Team Jack Apparel
  • Team Jack Accessories
  • Team Jack All Stars
  • Clearance Rack

Resources

  • CureSearch.org
  • CureTheKids.org
  • Dana-Farber.org

 
 

Join Our Fight!!!

News, events and research delivered to your inbox.

Committed to helping find a cure for pediatric brain cancer.

© Copyright Team Jack Foundation (All Rights Reserved)

Privacy Policy